Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Cancer Epidemiology, Survival, and Disparities: Past, Present, and Future
share announcement

Cancer Epidemiology, Survival, and Disparities: Past, Present, and Future

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: 28 November 2024 | Viewed by 461

Special Issue Editor

Dr. Adam Barsouk

E-Mail
Guest Editor
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Interests: thoracic oncology; genitourinary oncology; cancer epidemiology

Special Issue Information

Dear Colleagues,

With its rising incidence around the world, cancer is set to overtake heart disease as the leading cause of death in developed nations. Immuno- and targeted therapies have improved survival, but have in turn increased cancer prevalence, leading to a growing cohort of patients with immunosuppression and even secondary malignancies. Our therapeutic strides in oncology have also exacerbated the disparities in survival for underserved populations. Furthermore, cancer incidence among younger adults has increased many-fold over the past decade, with an unclear etiology. However, there is a silver lining. As many as 50% of cancer cases are believed to be preventable, with well-known risk factors such as smoking and sun exposure, and lesser-known risk factors such as radon exposure, aflatoxin, obesity, viruses and occupational exposure. This Special Issue aims  to elucidate the epidemiologic trends and risk factors that contribute to the global cancer burden, and examine trends in survival that can help reduce disparities and deliver equitable and accessible care worldwide.

Dr. Adam Barsouk
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epidemiology
  • survival
  • oncology
  • cancer
  • disparities

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 3309 KiB  
Article
A Cross-Sectional Analysis of Interventional Clinical Trials in High-Grade Glioma Therapy
by Angelo Angione, Jonathan Patterson, Ebrar Akca, Jessica Xu, Emily Xu, Vanessa Raab, Omar Elghawy, Adam A. Barsouk and Jonathan H. Sussman
Life 2024, 14(8), 926; https://doi.org/10.3390/life14080926 - 24 Jul 2024
Viewed by 248
Abstract
High-grade glioma is the most frequent and lethal primary tumor of the central nervous system. Despite advances in surgical, pharmacological, and cell-directed therapies, there have been no updates to the standard of care in over a decade. This cross-sectional study analyzes patient and [...] Read more.
High-grade glioma is the most frequent and lethal primary tumor of the central nervous system. Despite advances in surgical, pharmacological, and cell-directed therapies, there have been no updates to the standard of care in over a decade. This cross-sectional study analyzes patient and trial data from 201 interventional trials completed between 2010 and 2023, encompassing 18,563 participants. Although we found that all trials reported participant age and sex, only 52% of trials reported participant demographics, resulting in 51% of total participant demographics being unreported. The majority of studies did not report ethnicity, with approximately 60% of participants unreported. Additionally, males were significantly underrepresented in trials, comprising 60% of participants despite representing 75% of glioblastoma patients. Improved demographic reporting has been observed since 2011; however, it is inconsistent. Furthermore, we cataloged the geographic diversity of trials across the United States and found significant coverage deserts in relatively rural, but highly affected, areas such as Montana and Maine. We found a wider distribution of trials in both urban and wealthier regions, which indicates extensive coverage gaps and decreased access to participation for patients of a lower socioeconomic status. Full article
(This article belongs to the Special Issue Cancer Epidemiology, Survival, and Disparities: Past, Present, and Future)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop